Immunomic Therapeutics

1 follower


Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform.

Industries

Employees

11-50

Links

Org chart

Teri Heiland
Chief Scientific Officer
Frances Harrison
SVP, Regulatory Affairs
Cara Sholter
VP, Quality Assurance